Immunopeptidomics / neoantigen
6 workflows · 2012–2026
Immunopeptidomics / neoantigen: HLA-presented peptides, where non-specific processing makes the search space too large for a database and the interesting peptides are the ones not in it. 6 catalogued workflows and 8 papers.
HLA-presented peptides, where non-specific processing makes the search space too large for a database and the interesting peptides are the ones not in it.
| Workflows | 6 |
| Papers | 8 |
| Authors | 53 |
| Active | 2012-09-01 to 2026-09-04 |
Workflows (6)
- Melanoma HLA peptidome immunogenicity (2012): HLA class I peptidomes of four melanoma cell lines, extracted from isolated HLA, separated by two-dimensional HPLC and sequenced by MALDI post-source-decay MS. Spectra were interpreted twice over, by database-dependent Mascot search and by database-independent de novo sequencing in Sequit!, with synthetic peptides used to confirm assignments and to measure immunogenicity. Overlap between the four peptidomes was small, indicating highly individual HLA peptidomes, yet they were broadly immunogenic both in the patients the lines came from and in unrelated patients, and that cross-patient immunogenicity was only exceptionally attributable to individual peptides. Most epitopes came from low to medium abundance proteins in sensitive processes such as cell cycle control, DNA replication and tumour suppression.
- DeepNovoAA (2019): Immunopeptidome neoantigen discovery
- MARS (2022): Non-canonical antigen selection
- DeepNovo Peptidome (2023): Immunopeptidomics pipeline
- pXg (2024): MHC-I noncanonical peptides
- Thai RCC personalised immunopeptidomics (2026): Profiles the personalised immunopeptidomes of 13 Thai renal cell carcinoma patients, whose HLA allotypes are underrepresented in public reference data. Builds a personalised proteome from whole-exome sequencing and searches it alongside de novo peptide sequencing, so de novo produced part of the result.
Papers (8)
- High Immunogenicity of the Human Leukocyte Antigen Peptidomes of Melanoma Tumor Cells (2012, Journal of Biological Chemistry, peer-reviewed)
- Personalized deep learning of individual immunopeptidomes to identify neoantigens for cancer vaccines (2019, bioRxiv, preprint)
- Personalized deep learning of individual immunopeptidomes to identify neoantigens for cancer vaccines (2020, Nature Machine Intelligence, peer-reviewed)
- MARS: Improved De Novo Peptide Candidate Selection for Non-Canonical Antigen Target Discovery in Cancer (2022, Research Square, preprint)
- A complete mass spectrometry-based immunopeptidomics pipeline for neoantigen identification and validation (2023, Research Square, preprint)
- MARS an improved de novo peptide candidate selection method for non-canonical antigen target discovery in cancer (2024, Nature Communications, peer-reviewed)
- pXg: Comprehensive Identification of Noncanonical MHC-I-Associated Peptides From De Novo Peptide Sequencing Using RNA-Seq Reads (2024, Molecular & Cellular Proteomics, peer-reviewed)
- Mass Spectrometry-Based Profiling of Personalized Immunopeptidomes in Thai Renal Cell Carcinoma (2026, Journal of Proteome Research, peer-reviewed)
Sequencing tools these papers used
Where the work happened
Canada, China, Denmark, France, Germany, Netherlands, South Korea, Thailand, UK, USA